T-cells “à la CAR-T(e)” – Genetically engineering T-cell response against cancer

V. Eisenberg, Shiran Hoogi, A. Shamul, T. Barliya, Cyrille J. Cohen

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


The last decade will be remembered as the dawn of the immunotherapy era during which we have witnessed the approval by regulatory agencies of genetically engineered CAR T-cells and of checkpoint inhibitors for cancer treatment. Understandably, T-lymphocytes represent the essential player in these approaches. These cells can mediate impressive tumor regression in terminally-ill cancer patients. Moreover, they are amenable to genetic engineering to improve their function and specificity. In the present review, we will give an overview of the most recent developments in the field of T-cell genetic engineering including TCR-gene transfer and CAR T-cells strategies. We will also elaborate on the development of other types of genetic modifications to enhance their anti-tumor immune response such as the use of co-stimulatory chimeric receptors (CCRs) and unconventional CARs built on non-antibody molecules. Finally, we will discuss recent advances in genome editing and synthetic biology applied to T-cell engineering and comment on the next challenges ahead.

Original languageEnglish
Pages (from-to)23-40
Number of pages18
JournalAdvanced Drug Delivery Reviews
StatePublished - 15 Feb 2019

Bibliographical note

Publisher Copyright:
© 2019 Elsevier B.V.


  • CAR T cells
  • CCR
  • Chimeric Receptors
  • NK receptors
  • TCR gene transfer
  • Tumor Immunotherapy


Dive into the research topics of 'T-cells “à la CAR-T(e)” – Genetically engineering T-cell response against cancer'. Together they form a unique fingerprint.

Cite this